Retinal Disease Therapeutics Market Forecasts to 2030 – Global Analysis By Type (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters and Other Types), Disorder Type (Genetic and Age Relate

Retinal Disease Therapeutics Market Forecasts to 2030 – Global Analysis By Type (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters and Other Types), Disorder Type (Genetic and Age Related, Treatment Technique (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral Buckling and Vitrectomy), Dosage Form, Route of Administration, Distribution Channel, End User and by Geography

According to Stratistics MRC, the Global Retinal Disease Therapeutics Market is accounted for $13.99 billion in 2023 and is expected to reach $29.60 billion by 2030 growing at a CAGR of 11.3% during the forecast period. A collection of disorders known as retinal diseases impact the retina, the light-sensitive tissue found at the rear of the eye. These illnesses have the potential to impair the retina's normal function, which could result in blindness or visual impairment. Moreover, the goal of therapies for retinal diseases is to control and treat these conditions in order to maintain or enhance a patient's vision. Depending on the exact ailment and its severity, different treatment modalities may be used, such as medication, laser therapy, surgery, and implantable devices.

According to the World Vision Report released by the World Health Organisation (WHO), nearly 2.2 billion people suffer from vision impairment worldwide, of which approximately 60 million people are blind.

Market Dynamics:

Driver:

Expanding diabetes incidence

Retinal disease therapies are seeing significant growth due to the rise in diabetes cases worldwide, which is being caused by dietary and lifestyle modifications. Moreover, the increasing number of diabetes cases globally is directly correlated with an increased demand for therapeutics addressing diabetic retinal complications, as diabetes is a major risk factor for diabetic retinopathy, a condition that frequently results in vision impairment.

Restraint:

Lack of compliance with treatment

Frequent intravitreal injections are one of the ongoing, occasionally invasive treatments required for certain retinal diseases. Inconsistent adherence to these treatment plans may result from patient resistance brought on by discomfort, fear, or other issues. Additionally, poor adherence reduces the efficacy of therapeutic interventions and may jeopardize patients' long-term results. Improving treatment convenience and addressing patient concerns are essential for raising adherence rates.

Opportunity:

Developments in customized medicine

Personalized medicine in retinal disease therapeutics is made possible by the continuous integration of genomic and molecular data into clinical practice. Targeted therapies can be developed according to each patient's unique genetic composition thanks to thorough genetic profiling and biomarker analysis. Furthermore, precision medicine may advance significantly with this strategy, which aims to minimize side effects and optimize treatment efficacy.

Threat:

Affordability and economic barriers

The availability of treatments for retinal diseases may be severely hampered by economic inequality and high treatment expenses. In addition to restricting patient access, financial worries can put pressure on healthcare systems and make it more difficult to provide complete care. Recessions and other economic downturns have the potential to worsen these obstacles and put the fair distribution of cutting-edge retinal treatments in jeopardy.

Covid-19 Impact:

The market for treatments for retinal diseases has been greatly impacted by the COVID-19 pandemic. Diagnosis and treatment of retinal diseases have been delayed due to disruptions in healthcare systems, redirection of resources to pandemic response, and restrictions on patient access to routine care. Interruptions in clinical trials have impeded the development of new treatments. Furthermore, changes in healthcare priorities and economic uncertainty have affected market dynamics, potentially having long-term effects on funding for research and the development of treatments for retinal diseases. The pandemic has increased the use of telemedicine solutions in the treatment of retinal diseases and highlighted the significance of robust healthcare systems.

The Macular Degeneration segment is expected to be the largest during the forecast period

In the market for treatments for retinal diseases, the macular degeneration segment holds the largest share. Among older adults, macular degeneration—more specifically, age-related macular degeneration, or AMD—is a common and primary cause of vision loss. Moreover, the aging population on a global scale is driving the prominence of this segment. The macula, the core portion of the retina, is impacted by AMD, which can cause vision distortion or blurriness and, in extreme situations, central vision loss. Anti-VEGF medications and other targeted treatments meant to impede the advancement of the condition are available on the market for macular degeneration therapeutics.

The Home Healthcare segment is expected to have the highest CAGR during the forecast period

In the market, the Home Healthcare segment is growing at the highest CAGR. The need for patient-centered care, the aging population, and technological advancements that enable more complex treatments to be administered at home have all contributed to the rise in popularity of home healthcare. Additionally, a vast array of medical and non-medical treatments is included in home healthcare services, such as medication administration, chronic condition monitoring, and rehabilitation therapy delivered to patients in the comfort of their own homes.

Region with largest share:

In the global retinal disease therapeutics market, North America is expected to hold the largest share. The region's large and aging population, which makes it vulnerable to retinal diseases, its sophisticated healthcare infrastructure, and a thriving ecosystem of ophthalmic treatment-focused research and development activities all, contribute to its leadership. Major pharmaceutical companies, academic research centers, and cutting-edge healthcare facilities are some of the factors that consistently make North America a leader in the retinal disease therapeutics industry. A proactive regulatory environment that encourages innovation and speeds up the approval process for new treatments is another advantage that the region enjoys.

Region with highest CAGR:

In the market for treatments for retinal diseases, the Europe region is anticipated to have the highest CAGR. Benefits to the area include an established healthcare system, a high rate of age-related retinal diseases, and the early adoption of cutting-edge therapies. The United Kingdom, Germany, and France are among the European nations that place a high priority on ophthalmology research and development, which promotes improvements in the treatments for retinal diseases. Moreover, the notable growth in the region is also attributed to favourable regulatory frameworks and growing partnerships between pharmaceutical companies and academic institutions.

Key players in the market

Some of the key players in Retinal Disease Therapeutics market include Santen Pharmaceutical Co. Ltd., AbbVie Inc., Johnson & Johnson Services, Inc, Bayer AG, Regeneron Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Roche Holding AG, Genentech, Inc., Alcon Inc., Novartis AG, F. Hoffmann-La Roche AG, Senju Pharmaceutical Co., Ltd. , Bausch Health Companies Inc., Allergan plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Clearside Biomedical, Inc. and Kubota Pharmaceutical Holdings Co., Ltd.

Key Developments:

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company’s “Library of Libraries,” a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.

In July 2023, Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

In February 2023, AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.

Types Covered:
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters
• Other Types

Disorder Types Covered:
• Genetic
• Age Related

Treatment Techniques Covered:
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Dosage Forms Covered:
• Gels
• Eye solutions
• Capsules & Tablets
• Eye Drops
• Ointments
• Other Dosage Forms

Route of Administrations Covered:
• Oral
• Topical
• Intravitreal

Distribution Channels Covered:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Direct Tender
• Other Distribution Channels

End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements